• Amyloid β-Peptide (1-42): Workflows & Optimization in AD Res

  2026-05-12

  Unlock robust Alzheimer's disease models using Amyloid β-Peptide (1-42) (Aβ42) with precise, evidence-backed workflows. Discover advanced assay enhancements, troubleshooting strategies, and insights from key reference studies to maximize neurotoxicity and ion channel modulation research.

• Proteoform-Specific Drug Targeting in Native Cell Signaling

  2026-05-11

  This article examines a recent Nature Chemistry study that pioneers native top-down mass spectrometry for mapping drug-protein interactions at the proteoform level within unmodified lipid bilayers. The findings reveal differential off-target binding of cGMP-specific phosphodiesterase type 5 inhibitors, such as sildenafil, to distinct retinal proteoforms, offering new insights for personalized drug design.

• Lipoamino Bundle LNPs Enable Spleen-Targeted mRNA Delivery

  2026-05-11

  This study introduces lipoamino bundle lipid nanoparticles (LNPs) as a chemically evolved platform for efficient mRNA transfection of dendritic cells and macrophages, with pronounced spleen-selectivity in vivo. The work provides mechanistic insights into LNP design for immune-targeted mRNA delivery, significant for vaccine and immunotherapy research.

• Precision in Coagulation: Advanced Utility of Thrombin B Cha

  2026-05-10

  Explore the pivotal role of thrombin, a trypsin-like serine protease, in orchestrating fibrinogen to fibrin conversion and vascular modeling. This article uniquely analyzes assay implications and practical considerations for using Coagulation Factor II (Thrombin) B Chain Fragment [Homo sapiens], providing researchers with a distinctive, evidence-driven perspective.

• ddhCTP (3ʹ-deoxy-3′,4ʹ-didehydro-CTP): Mechanism, Evidence,

  2026-05-09

  ddhCTP is a biologically derived RNA virus replication inhibitor produced via viperin’s radical SAM enzymatic activity. This nucleotide analog interrupts viral RNA synthesis by targeting viral polymerases, with demonstrated efficacy against flaviviruses in cell and animal models. Its application enables precise benchmarking in antiviral drug development and mechanistic studies.

• Technical Guide: Angiotensin I/II (1-5) in Hypertension Rese

  2026-05-09

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide for modeling blood pressure regulation and aldosterone release within the renin-angiotensin system. It is suitable for cardiovascular and renal workflows but should not be used in unrelated peptide signaling studies or outside its validated solubility and mechanistic context.

• Hypoxia and Immunometabolism: Mechanisms in Tumor Microenvir

  2026-05-08

  This review dissects the mechanisms by which hypoxia and immune metabolism co-shape the tumor microenvironment, emphasizing metabolic reprogramming and immune evasion. The findings have practical implications for research targeting redox state and oxidative stress in cancer.

• Zosuquidar (LY335979) 3HCl for Reliable MDR Reversal in Canc

  2026-05-07

  This article presents actionable, scenario-driven guidance for overcoming multidrug resistance (MDR) in cell-based assays using Zosuquidar (LY335979) 3HCl (SKU A3956). Drawing on validated data and practical experience, it addresses common laboratory pitfalls, protocol optimization, and product selection, ensuring robust and reproducible results for biomedical researchers.

• Tamoxifen in Research: Protocol Precision and Troubleshootin

  2026-05-07

  Tamoxifen’s dual role as a selective estrogen receptor modulator and CreER gene knockout inducer empowers versatile experimental design. This guide delivers actionable workflows, protocol optimization, and troubleshooting insights—grounded in recent breakthroughs and APExBIO’s validated product quality.

• Dual-Action Kinase Inhibitors Expedite p38α Dephosphorylatio

  2026-05-06

  The referenced study reveals that certain kinase inhibitors, including indole-5-carboxamide derivatives, can simultaneously block the p38α MAPK active site and enhance its dephosphorylation by phosphatases. This dual-action mechanism offers new avenues for improving specificity and efficacy in research on inflammation, apoptosis, and neuroregeneration.

• CD44-Driven Metabolic Rewiring in IDH-Mutant Leukemia: New T

  2026-05-06

  This article reviews recent evidence that CD44-mediated metabolic rewiring is a critical dependency in IDH-mutant acute myeloid leukemia (AML). The reference study uncovers a feedforward pathway sustaining oncometabolite production and highlights new avenues for therapeutic intervention, including combined metabolic and IDH-mutant enzyme inhibition.

• Ziprasidone HCl: Bridging Neuropharmacology and Oncology

  2026-05-05

  This thought-leadership article explores how Ziprasidone Hydrochloride (Ziprasidone HCl) is redefining the translational research landscape by uniting dopaminergic and serotonergic signaling studies with innovative metabolic reprogramming strategies in cancer. We provide mechanistic insight, protocol guidance, and a strategic roadmap for researchers seeking to harness this agent’s unique dual-action profile.

• PPARγ Activation Modulates Macrophage Polarization in IBD Mo

  2026-05-05

  This study demonstrates that activation of PPARγ, including by pioglitazone, regulates macrophage polarization and ameliorates dextran sulfate sodium-induced inflammatory bowel disease by modulating the STAT-1/STAT-6 pathway. These findings clarify molecular mechanisms underlying inflammation resolution and provide a framework for future IBD and immunomodulation research.

• Cdk5-AMPK Axis Modulates Microglial Ferroptosis in Ischemic

  2026-05-04

  This study elucidates how Cdk5 downregulation mitigates neuronal ferroptosis in ischemic stroke models by modulating the AMPK pathway and microglial polarization. The findings highlight actionable targets for neuroprotection and showcase methodological advances relevant for iron metabolism research.

• Ziprasidone Hydrochloride: GOT1 Inhibition & Oncology Benchm

  2026-05-04

  Ziprasidone hydrochloride (Ziprasidone HCl) is a second-generation antipsychotic with validated activity as a GOT1 inhibitor, disrupting tumor glutamine metabolism and inhibiting proliferation in pancreatic cancer models. The compound demonstrates specific in vitro and in vivo benchmarks with clear mechanistic rationale. APExBIO supplies high-purity Ziprasidone HCl (A5350) for advanced translational research.

444 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page